{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:07:25Z","timestamp":1779944845568,"version":"3.53.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) accounts for approximately 3\u20137% of all NSCLCs and predominantly affects young, never-smoker patients. Lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), has demonstrated significant efficacy as first-line therapy. However, its exclusive oral formulation poses a challenge in patients with dysphagia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 30-year-old woman with metastatic ALK-positive NSCLC who presented with severe dysphagia due to bulky supraclavicular and laterocervical lymphadenopathy compressing the cervical oesophagus. Given the impossibility of swallowing, lorlatinib 100 mg daily was administered via a nasogastric tube after tablet crushing. Within days, rapid reduction of cervical lymph node swelling was observed, swallowing improved, and the patient resumed oral intake. Imaging performed two weeks later showed partial response; at six months, PET-CT demonstrated complete metabolic response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case supports the feasibility and effectiveness of lorlatinib administration via the enteral route in patients unable to swallow. Despite the lack of formal evidence for alternative formulations, pharmacokinetic data suggest adequate absorption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Crushed lorlatinib administered through a nasogastric tube represents a practical and effective option for dysphagic patients with ALK-positive NSCLC requiring early target-directed therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1840539","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:54:14Z","timestamp":1779944054000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Luca Carlofrancesco","family":"Ammoni","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Carola","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ippolito","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Baggi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Consoli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pedrazzini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-08-1018","article-title":"Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts","volume":"14","author":"Takeuchi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1056\/nejmoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"373","author":"Solomon","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/s0140-6736(17)30123-x","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.11.004","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","unstructured":"https:\/\/www.ema.europa.eu"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.280","article-title":"Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer","volume":"13","author":"Wu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00280-021-04368-1","article-title":"Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase\/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants","volume":"89","author":"Hibma","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/jm500261q","article-title":"Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations","volume":"57","author":"Johnson","year":"2014","journal-title":"J Med Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1774552","article-title":"Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer","volume":"21","author":"El Darsa","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7574369","article-title":"Pharmacokinetic study and tissue distribution of lorlatinib in mouse serum and tissue samples by liquid chromatography-mass spectrometry","volume":"2019","author":"Chen","year":"2019","journal-title":"J Anal Methods Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.796","article-title":"Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report","volume":"9","author":"Sasaki","year":"2021","journal-title":"Respirol Case Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3892\/ol.2023.14113","article-title":"Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase\u2011positive non\u2011small cell lung cancer: A case report","volume":"26","author":"Wang","year":"2023","journal-title":"Oncol Lett"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220988577","article-title":"The continuing importance of oncology case reports","volume":"27","author":"Gilbar","year":"2021","journal-title":"J Oncol Pharm Pract"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1840539\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:54:29Z","timestamp":1779944069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1840539\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1840539"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1840539","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1840539"}}